science
Eli Lilly to Acquire Three Early-Stage Vaccine Developers
Eli Lilly announced Tuesday it will purchase three vaccine companies for a combined total that could reach nearly $4 billion. The acquisitions expand the company's presence in infectious-disease research.
May 26, 7:29 AM·1m read1 source
StatAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Eli Lilly said Tuesday it will acquire three early- and mid-stage vaccine developers. The companies are Curevo, LimmaTech Biologics, and Vaccine Company. The deals could cost up to nearly $4 billion in total. Eli Lilly stated the purchases continue a series of acquisitions the company has made in recent months.
Lilly has bought firms focused on cancer, autoimmune diseases, and sleep disorders. Each of those transactions was valued under $10 billion. The company attributed its acquisition capacity to revenue from its GLP-1 products. The three vaccine developers are working on shots against pathogens that can cause long-term health issues.
Transparency
How sources framed this
Single source — no framing comparison available.
CorroborationModerate · 1 source
